DBVT - Shares of DBV Technologies S.A. (DBVT) Exceed 52-Week High
Shares of DBV Technologies S.A. (NASDAQ:DBVT) traded at a new 52-week high today of $50.24. So far today approximately 39.1 million shares have been exchanged, as compared to an average 30-day volume of 154,000 shares.
DBV Technologies S.A. has overhead space with shares priced $1.45, or 15.2% below the average consensus analyst price target of $1.71.
DBV Technologies SA is a biotechnology company that provides therapy for food and pediatric allergy patients. The company focuses on discovering, developing, manufacturing, and commercializing treatments for severe allergies in the United States and other global markets. Its method of delivering biologically active compounds to the immune system is through self-administered and non-invasive products. It also explores potential applications of its platform in vaccines and other immune diseases.
In the past 52 weeks, DBV Technologies S.A. share prices are bracketed by a low of $1.20 and a high of $50.24 and is now at $1.45, 21% above that low price.
Receive IBN Spotlights - "Bite Size" Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer